U.S. markets close in 1 hour 41 minutes
  • S&P 500

    4,175.91
    +63.41 (+1.54%)
     
  • Dow 30

    34,406.27
    +384.82 (+1.13%)
     
  • Nasdaq

    13,417.69
    +292.70 (+2.23%)
     
  • Russell 2000

    2,216.28
    +45.32 (+2.09%)
     
  • Crude Oil

    65.25
    +1.43 (+2.24%)
     
  • Gold

    1,839.80
    +15.80 (+0.87%)
     
  • Silver

    27.38
    +0.32 (+1.19%)
     
  • EUR/USD

    1.2142
    +0.0057 (+0.47%)
     
  • 10-Yr Bond

    1.6420
    -0.0260 (-1.56%)
     
  • GBP/USD

    1.4095
    +0.0044 (+0.31%)
     
  • USD/JPY

    109.4050
    -0.0290 (-0.03%)
     
  • BTC-USD

    50,663.28
    +2,223.74 (+4.59%)
     
  • CMC Crypto 200

    1,419.68
    +61.12 (+4.50%)
     
  • FTSE 100

    7,043.61
    +80.28 (+1.15%)
     
  • Nikkei 225

    28,084.47
    +636.46 (+2.32%)
     

SHAREHOLDER ALERT: EBIX APA ATNX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / April 12, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Ebix, Inc. (NASDAQ:EBIX)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/ebix-inc-loss-submission-form?prid=14606&wire=1
Lead Plaintiff Deadline: April 23, 2021
Class Period: November 9, 2020 - February 19, 2021

Allegations against EBIX include that: (1) there was insufficient audit evidence to determine the business purpose of certain significant unusual transactions in Ebix's gift card business in India during the fourth quarter of 2020; (2) there was a material weakness in Company's internal controls over the gift or prepaid revenue transaction cycle; and (3) the Company's independent auditor was reasonably likely to resign over disagreements with Ebix regarding $30 million that had been transferred into a commingled trust account of Ebix's outside legal counsel; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Apache Corporation (NASDAQ:APA)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/apache-corporation-loss-submission-form?prid=14606&wire=1
Lead Plaintiff Deadline: April 26, 2021
Class Period: September 7, 2016 - March 13, 2020

Allegations against APA include that: (i) Apache intentionally used unrealistic assumptions regarding the amount and composition of available oil and gas in Alpine High; (ii) Apache did not have the proper infrastructure in place to safely and/or economically drill and/or transport those resources even if they existed in the amounts purported; (iii) these misleading statements and omissions artificially inflated the value of the Company's operations in the Permian Basin; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Athenex, Inc. (NASDAQ:ATNX)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/athenex-inc-loss-submission-form?prid=14606&wire=1
Lead Plaintiff Deadline: May 3, 2021
Class Period: August 7, 2019 - February 26, 2021

Allegations against ATNX include that: (i) the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (ii) the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR; (iii) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (iv) the Company's Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; (v) as a result, it was foreseeable that the FDA would not approve the Company's NDA in its current form; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong



View source version on accesswire.com:
https://www.accesswire.com/640076/SHAREHOLDER-ALERT-EBIX-APA-ATNX-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines